Long-term clinical outcome of sirolimus-eluting stent implantation in metabolic syndrome and diabetes

Journal of Invasive Cardiology

Volumn 22, Issue 7, 2010, Pages 317-321

  Almalla, Mohammad ^a   Schröder, Jörg ^a   Deserno, Verena ^a   Vogt, Felix ^a   Koos, Ralf ^a   Koch, Karl Christian ^a   Marx, Nikolaus ^a   Hoffmann, Rainer ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

diabetes; drugs; metabolic syndrome; restenosis; stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; GLUCOSE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DIET RESTRICTION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; OBESITY; OUTCOME ASSESSMENT; STATISTICAL SIGNIFICANCE; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY DISEASE; CORONARY THROMBOSIS; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; SIROLIMUS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77957090306     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Marroquin OC, Kip KE, Kelley DE, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: A report from the Women's Ischemia Syndrome Evaluation. Circulation 2004;109:714-721.
2. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
3. Alexander CM. The coming of age of metabolic syndrome. Diabetes Care 2003;26:3180-3181.
4. Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 2004;27:990-994.
5. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998;32:584-589.
6. Takagi T,Yoshida K, Akasaka T, et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients. J Am Coll Cardiol 2002;36:731-738.
7. Hong SJ, Kim MH, Ahn TH, et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in diabetic patients. Heart 2006;92:1119-1124.
8. Moussa I, Leon MB, Baim DS. Impact of sirolimus eluting stents on outcome in diabetic patients. A SIRIUS (Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Coronary Artery Lesions) substudy. Circulation 2004;109:2273-2278.
9. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. Brit Med J 1995;311:158-161.
10. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397.
11. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-2752.
12. Scheen AJ, Warze'e F, Legrand VMG. Drug-eluting stents: Metaanalysis in diabetic patients. Eur Heart J 2004;25:2167-2168.
13. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non- ST-segment elevation acute coronary syndromes. Eur Heart J 2004;25:190-198.
14. Weisz G, Leon MB, Holmes DR. Five-year follow-up after sirolimus-eluting stent implantation. Results of the SIRIUS Trial. J Am Coll Cardiol 2009;53:1488-1497.
15. Dibra A, Kastrati A, Mehilli J, et al; ISAR-DIABETES Study Investigators. Paclitaxeleluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-670.
16. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092.
17. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of firstgenreation drug-eluting stents: Cause for concern. Circulation 2007;115:1440-1455.
18. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stent in coronary artery disease: A meta-analysis. Eur Heart J 2006;27:2784-2814.
19. de la Torre-Hernández JM, Alfonso F, Hernández F, et al. Drug-eluting stent thrombosis: Results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008;51:986-990.
20. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007;369:667-678.
21. West NE, Ruygrok PN, Disco CM, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004;109:867-873.
22. Niles NW, McGrath PD, Malenka D, Group. NNECDS. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: Results of a large regional prospective study. J Am Coll Cardiol 2001;37:1008-1015.
23. Lincoff AM. Important triad in cardiovascular medicine: Diabetes, coronary intervention and platelet glycoprotein IIb/IIIa receptor blokade. Circulation 2003;107:1556-1559.
24. Cola C, Sabaté M. Revascularization in high risk patients: Diabetes mellitus. Minerva Cardioangiol 2007;55:557-577.
25. Angiolillo DJ. Antiplatelet therapy in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007;14:124-131.
26. Gurbel PA, Blinden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST study. J Am Coll Cardiol 2005;46:1827-1832.
27. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317.
28. Freeman DJ, Norrie J, Caslake MJ, et al. West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-1600.
29. Han TS, Williams K, Sattar N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 2002;10:923-931.